Although GCPII inhibition has therapeutic potential for the treatment of cognitive disorders, the subcellular expression of GCPII in layer III of the primate dlPFC and the effects of GCPII inhibition on higher cognition in nonhuman primates are not known. Here, FOLH1 is linked to cognitive disorder.